Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.54 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.54 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.54 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800712 | 0.91 | ALDH1A1 (0.78) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL922597 | 0.88 | ALDH1A1 (0.70) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL922442 | 0.86 | ALDH1A1 (0.68) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL3568406 | 0.86 | ALDH1A1 (0.68) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL18423069 | 0.85 | ALDH1A1 (0.64) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL2716970 | 0.84 | ALDH1A1 (0.73) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL2657985 | 0.84 | ALDH1A1 (0.65) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL374227 | 0.84 | ALDH1A1 (0.73) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL30560053 | 0.84 | ALDH1A1 (0.67) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL29531890 | 0.84 | ALDH1A1 (0.65) | ALDH1A1KDM4ETDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5753679-A | SCIZOPHRENIA | HOFFMANN-LA ROCHE INC. (US) | 1998-05-19 | — | — | US | claimed |
| CN-106517049-B | 360 ° of large parts turnover devices of one kind and its working method | 江苏建筑职业技术学院 | 2018-07-20 | — | — | CN | disclosed |
| CN-104211685-A | Thiomorpholine compounds containing substituted pyrrole alkyl groups | INST MATERIA MEDICA CAMS | 2014-12-17 | — | — | CN | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1331010-A1 | PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | ALDH1A1 3946/4885KDM4E 4438/4885TDP1 666/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | ALDH1A1 3946/4885KDM4E 4438/4885TDP1 666/4885 |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | UTS2R, PRSS12, CTSA | ALDH1A1 3567/4885KDM4E 4866/4885TDP1 1836/4885 |
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | ALDH1A1 2561/4885KDM4E 2148/4885TDP1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.